Title |
Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
|
---|---|
Published in |
Neurological Sciences, June 2019
|
DOI | 10.1007/s10072-019-03959-4 |
Pubmed ID | |
Authors |
Cristina Scarpazza, Nicola De Rossi, Giulietta Tabiadon, Maria Vittoria Turrini, Simonetta Gerevini, Ruggero Capra |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 33% |
United Kingdom | 1 | 17% |
Serbia | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 67% |
Scientists | 1 | 17% |
Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 29 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 17% |
Other | 5 | 17% |
Student > Bachelor | 3 | 10% |
Researcher | 2 | 7% |
Student > Postgraduate | 2 | 7% |
Other | 5 | 17% |
Unknown | 7 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 41% |
Neuroscience | 3 | 10% |
Psychology | 2 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Social Sciences | 1 | 3% |
Other | 1 | 3% |
Unknown | 9 | 31% |